{
    "clinical_study": {
        "@rank": "126180", 
        "arm_group": [
            {
                "arm_group_label": "MK-1293 / Lantus\u2122 / MK-1293 / Lantus\u2122", 
                "arm_group_type": "Experimental", 
                "description": "MK-1293 or Lantus\u2122 0.4 units/kg administered subcutaneously on Day 1 of 4 alternating study periods."
            }, 
            {
                "arm_group_label": "Lantus\u2122 / MK-1293 / Lantus\u2122 / MK-1293", 
                "arm_group_type": "Experimental", 
                "description": "MK-1293 or Lantus\u2122 0.4 units/kg administered subcutaneously on Day 1 of 4 alternating study periods."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety, pharmacokinetics, and pharmacodynamics of\n      MK-1293 compared with a basal insulin (Lantus\u2122) in participants with Type 1 Diabetes. The\n      primary hypotheses are that the duration of action, pharmacodynamic profile, and\n      pharmacokinetic profile of MK-1293 and the comparator basal insulin are similar."
        }, 
        "brief_title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has type 1 diabetes mellitus diagnosed at least 12 months before screening\n\n          -  Subject to investigator discretion, is on a stable dose of insulin for at least 2\n             weeks before screening\n\n          -  Has a total daily insulin dose <=1.2 units/kg\n\n          -  Has a screening hemoglobin A1c <9.5%\n\n          -  Has a body mass index >18.0 and <=30.0 kg/m^2\n\n          -  Has a weight >=50 kg\n\n          -  Female participant of reproductive potential has a serum beta-human chorionic\n             gonadotropin level consistent with the nongravid state and agrees to use (and/or have\n             her partner use) 2 acceptable methods of birth control until 2 weeks after the last\n             dose of study drug\n\n          -  Postmenopausal female participant is without menses for >=1 year\n\n          -  Surgically sterile female participant status is post hysterectomy, oophorectomy, or\n             tubal ligation\n\n          -  Has not used nicotine or nicotine-containing products for at least 3 months before\n             study start or smokes less than 10 cigarettes per day and is willing to abstain\n             during the trial\n\n        Exclusion Criteria:\n\n          -  Has a history of clinically significant gastrointestinal, cardiovascular,\n             hematological, hepatic, immunological, renal, respiratory, genitourinary, or major\n             neurological abnormalities or disease\n\n          -  Has a history of clinically significant endocrine abnormalities or diseases except\n             type 1 diabetes mellitus\n\n          -  Has had any severe hypoglycemic episodes associated with hypoglycemic seizures,\n             comas, or unconsciousness within the past 3 months\n\n          -  Has a history of diabetic ketoacidosis within the past 6 months\n\n          -  Has a history of significant multiple or severe allergies, anaphylactic reaction, or\n             significant intolerability to drugs or food\n\n          -  Has a history of hypersensitivity to pharmacologic insulins\n\n          -  Is positive for hepatitis B surface antigen, hepatitis C, or HIV\n\n          -  Has had major surgery or donated or lost 1 unit of blood within 4 weeks before\n             screening\n\n          -  Unable to refrain from use of any medication or herbal remedy from 2 weeks prior to\n             the first dose of study drug to until the posttrial visit. Some medications are\n             permitted and may be discussed with the investigators\n\n          -  Vaccination within 12 weeks of start of study participation\n\n          -  Consumes >3 glasses of alcoholic beverages per day. Participants consuming 4 glasses\n             of alcoholic beverages may be enrolled at the discretion of the investigator.\n\n          -  Consumes >6 servings of caffeinated beverages per day\n\n          -  Is a regular user of any illicit drugs or has a history of drug abuse (including\n             alcohol) within approximately 1 year\n\n          -  Is on a carbohydrate-restricted diet (<100 grams carbohydrate per day); participants\n             who are on a carbohydrate-restricted diet may be included if they agree to a diet\n             consisting of >=100 grams of carbohydrate daily throughout the study\n\n          -  Has a personal or family history of hypercoagulability or thromboembolic disease\n\n          -  Has used systemic glucocorticoids within 3 months of screening or anticipates\n             treatment with systemic glucocorticoids during study participation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02059174", 
            "org_study_id": "1293-005", 
            "secondary_id": "2012-005656-41"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MK-1293 / Lantus\u2122 / MK-1293 / Lantus\u2122", 
                    "Lantus\u2122 / MK-1293 / Lantus\u2122 / MK-1293"
                ], 
                "description": "MK-1293 0.4 units/kg administered subcutaneously", 
                "intervention_name": "MK-1293", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-1293 / Lantus\u2122 / MK-1293 / Lantus\u2122", 
                    "Lantus\u2122 / MK-1293 / Lantus\u2122 / MK-1293"
                ], 
                "description": "Lantus\u2122 0.4 units/kg administered subcutaneously", 
                "intervention_name": "Lantus\u2122", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MK-1293 / Lantus\u2122 / MK-1293 / Lantus\u2122", 
                    "Lantus\u2122 / MK-1293 / Lantus\u2122 / MK-1293"
                ], 
                "description": "Participants will receive an intravenous infusion of insulin aspart (Novolog\u2122 or other rapid-acting insulin analog) for several hours prior to MK-1293 or Lantus\u2122dosing in each dosing period to meet basal insulin requirements", 
                "intervention_name": "Novolog\u2122", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chula Vista", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "91911"
                }, 
                "name": "Call for Information (Investigational Site 0002)"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single Dose Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-1293 and to Compare Its Pharmacologic Properties to Those of Another Basal Insulin in Subjects With Type I Diabetes", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacodynamics (PD): Duration of Pharmacodynamic Action", 
                "safety_issue": "No", 
                "time_frame": "Up to 30 hours after dosing"
            }, 
            {
                "measure": "PD: Area Under the Glucose Infusion Rate Versus Time Curve Over 24 Hours After Dosing (GIR-AUC0-24hr)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after dosing"
            }, 
            {
                "measure": "PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the First 12 Hours After Dosing (GIR-AUC0-12hr)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 hours after dosing"
            }, 
            {
                "measure": "PD: Area Under the Glucose Infusion Rate Versus Time Curve Over the Second 12 Hours After Dosing (GIR-AUC12-24hr)", 
                "safety_issue": "No", 
                "time_frame": "From 12 to 24 hours after dosing"
            }, 
            {
                "measure": "PD: Maximum Glucose Infusion Rate (GIRmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after dosing"
            }, 
            {
                "measure": "Pharmacokinetics (PK): Area Under the Plasma Concentration Versus Time Curve (AUC0-24)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after dosing"
            }, 
            {
                "measure": "PK: Maximum Plasma Concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 hours after dosing"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02059174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PK: Area Under the Plasma Concentration Versus Time Curve Over the First 12 Hours After Dosing (AUC0-12)", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 hours after dosing"
            }, 
            {
                "measure": "PK: Area Under the Plasma Concentration Versus Time Curve Over the Second 12 Hours After Dosing (AUC12-24)", 
                "safety_issue": "No", 
                "time_frame": "From 12 to 24 hours after dosing"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}